Quick Dispatch:
Your soul study semaglutide Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your soul study semaglutide Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design ships.
Need Help?
Questions about soul study semaglutide Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for soul study semaglutide Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design in your area.
Rethinking the Standard of Care:
22.11
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
25.80
SOUL Trial (NEJM 2025): Oral semaglutide led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine
25.05
Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care?
21.89
Canadian Perspectives 2025 Whiteboard on the SOUL Trial
24.79
Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme - Thethi - 2020 - Diabetes, Obesity and Metabolism
23.08
Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients
23.69
